How to Quit Vaping With Bupropion (Wellbutrin/Zyban): Dosing, Timeline, and What to Expect

Bupropion is the cessation pharmacology most users do not think about — it lives in varenicline’s shadow on efficacy and in NRT’s shadow on accessibility — but for a specific subset of quitters, it is the right tool. It works through a completely different mechanism than nicotine-replacement or nicotinic-receptor partial agonists, which makes it the option of choice for users who have failed varenicline, who have a history of depression, who cannot tolerate the nausea profile of varenicline, or who want to address vape-driven mood symptoms and nicotine dependence with a single drug. This guide covers the evidence base, dosing schedule, expected timeline, side effects, and when to choose bupropion over alternatives.

For broader pharmacological context, our Chantix alternatives and prescription drugs guides cover the full cessation pharmacology landscape, and our cytisinicline explainer covers the upcoming third option.

What Bupropion Is and Isn’t

Bupropion is a prescription antidepressant in the aminoketone class, marketed under the brand names Wellbutrin (for depression) and Zyban (specifically for smoking cessation). It is the same molecule at the same doses; only the labeling differs. As a cessation drug, bupropion was first FDA-approved in 1997 — the second cessation pharmacology ever approved in the U.S., after nicotine gum in 1984.

Mechanism: bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It increases dopamine availability in the brain’s reward circuit and modestly blocks nicotinic receptors. For a vaping quitter, both effects matter — the dopamine effect helps replace the dopamine signal that nicotine was providing, dampening withdrawal-driven mood symptoms and cravings, and the receptor blockade reduces the rewarding effect of any nicotine that does enter the system.

Bupropion is not nicotine. It does not replace nicotine in the bloodstream. That makes it pharmacologically distinct from NRT (patches, gum, lozenges, pouches) and from nicotine-receptor partial agonists (varenicline, cytisinicline). For users specifically trying to avoid any further nicotine exposure during a quit, bupropion is the cessation drug that delivers no nicotine.

Efficacy: What the Data Shows

Bupropion’s clinical efficacy in smoking cessation is well-documented across decades of trials. The Cochrane review of cessation pharmacotherapies summarizes:

• Bupropion vs. placebo: roughly doubles long-term quit rates. Six-month continuous abstinence rates run 16-22% on bupropion vs. 8-12% on placebo (Cochrane Review, 2023).
• Bupropion vs. varenicline: varenicline is more effective in most head-to-head trials. Pooled efficacy data shows 29.7% continuous abstinence on bupropion vs. 44.0% on varenicline at weeks 9-12 (Pulmonology Advisor, 2024).
• Bupropion vs. NRT: Roughly equivalent efficacy to single-agent NRT in head-to-head trials, with some evidence favoring bupropion modestly.
• Bupropion + NRT combination: Adding bupropion to nicotine patch produces a small additional efficacy bump over either alone, useful for hard cases.

For vaping cessation specifically, the trial evidence is thinner than for smoking cessation. The pharmacological logic transfers directly — vaping and smoking both involve nicotine dependence — but clinical trials specifically powered for vaping cessation are limited. The CDC and most cessation clinicians treat bupropion as appropriate for vaping cessation by extrapolation from smoking-cessation data.

For users specifically interested in the bupropion-vs-varenicline trade-off, our chantix alternatives guide covers the choice in detail.

Dosing Schedule

Standard bupropion sustained-release (SR) cessation dosing:

Days 1-3: 150 mg once daily in the morning. Days 4-7: 150 mg twice daily, doses spaced at least 8 hours apart. Week 2 and beyond: Continue at 150 mg twice daily for the full course (typically 7-12 weeks).

Critical detail on starting timing: bupropion takes approximately 7-14 days to reach therapeutic effect for cessation. You start bupropion 1-2 weeks before your quit date, not on the quit date itself. During the pre-quit period, you continue vaping at your usual pattern while the drug builds to effective plasma levels.

Quit date: typically set for the start of week 2 of bupropion (day 8-14). At that point, you stop vaping and rely on bupropion plus any breakthrough NRT or behavioral support for the cessation window.

Course duration: standard is 7-12 weeks total. Some clinicians extend bupropion through 6 months for users with high relapse risk or co-occurring depression.

Bupropion extended-release (XL) forms are available with once-daily dosing (300 mg in the morning), which improves adherence vs. twice-daily SR. XL is typically used off-label for cessation rather than the formally FDA-approved SR schedule, but the clinical effect is comparable.

Timeline: What to Expect Week by Week

Week 0 (pre-start). Bupropion is not yet started. Prescriber visit, lab work if needed, prescription filled. Set quit date 1-2 weeks out.

Week 1. Start bupropion. Continue vaping at usual pattern. Possible early side effects: insomnia (the most common early effect — bupropion is mildly stimulating), dry mouth, headache, mild nausea. Most early effects resolve within 7-10 days.

Week 2. Increase to twice-daily dosing. Quit date typically falls in this window. Withdrawal symptoms emerge as vape use stops — cravings, irritability, difficulty concentrating, anxiety. Bupropion’s dopamine effect partially blunts these symptoms but does not eliminate them. NRT (lozenges, gum, pouches) can be added for breakthrough cravings — bupropion plus NRT is a recognized combination protocol. Our combination NRT patch + lozenge guide covers the over-the-counter side of the stack.

Week 3-4. Withdrawal peaks and begins to fade. The most challenging window. Bupropion is at full effect; cravings are intense but blunted; mood is variable. For users with co-occurring depression, this is also typically when antidepressant effects of bupropion start to register independently.

Week 5-8. Stabilization phase. Acute withdrawal symptoms have largely resolved. Bupropion continues at full dose. Quit confidence builds. Behavioral patterns rewire around non-vaping defaults. Our quit vaping 30-day plan and scheduled reduction method guides cover the behavioral scaffold.

Week 9-12. End-of-treatment window. Most users complete the bupropion course in this window. Some clinicians taper down at the end of treatment; others stop abruptly. Bupropion has minimal discontinuation syndrome compared to other antidepressants, so abrupt discontinuation is usually tolerable.

Post-treatment. The most important window for long-term success. Many quitters experience a craving resurgence in weeks 2-4 after stopping bupropion as the drug clears the system. Pre-plan how you’ll handle this window — increased NRT, behavioral support, app-based check-ins. Our vape relapse recovery framework covers the late-relapse risk profile.

Side Effects: What to Watch For

The bupropion side effect profile is meaningfully different from varenicline’s and merits careful review.

Common and usually mild: Insomnia (10-20% of users), dry mouth (10%), headache (10%), nausea (5-10%), constipation. Most resolve within the first 7-14 days. Taking the second dose no later than 5 PM helps with insomnia.

Less common but more significant: Anxiety or agitation in the first 2 weeks (typically resolves). Modest weight loss (usually 1-3 lbs, distinct from the weight-gain effect of nicotine cessation — bupropion partially offsets the weight gain that typically accompanies quitting; our nicotine metabolism weight gain explainer covers the underlying mechanism). Reduced appetite.

Important contraindications and risks:

• Seizure risk. Bupropion lowers the seizure threshold. Patients with a history of seizure disorder, eating disorders (bulimia or anorexia in particular), severe head injury, or active alcohol withdrawal should not take bupropion. The seizure rate at standard cessation doses is approximately 0.1%, but rises significantly above 450 mg/day, with eating disorders, or with concurrent CNS-active drugs.
• Psychiatric effects. Like all antidepressants, bupropion carries an FDA black-box warning for increased suicidal thinking in young adults under 25 in the first weeks of treatment. Most users do not experience this, but monitoring is appropriate. Patients with active bipolar disorder need careful screening — bupropion can trigger mania.
• Drug interactions. MAO inhibitors (must wait 14 days after stopping MAOIs to start bupropion), tamoxifen (bupropion is a strong CYP2D6 inhibitor and reduces tamoxifen’s activation), some HIV antiretrovirals, and other CYP2B6 inhibitors.
• Hypertension. Bupropion can modestly increase blood pressure. Users with uncontrolled hypertension should have BP managed before starting.

For users without contraindications, bupropion is well tolerated and the side effect profile is meaningfully gentler than varenicline’s nausea-and-dreams profile in most users.

When to Choose Bupropion Over Other Options

Choose bupropion if:

• You have co-occurring depression or a history of depression. Bupropion treats both conditions simultaneously.
• You have failed varenicline due to nausea, abnormal dreams, sleep disturbance, or mood effects.
• You specifically do not want any further nicotine exposure during your quit (rules out NRT).
• You are concerned about weight gain after quitting. Bupropion modestly suppresses appetite and partially offsets the typical 5-10 lb cessation weight gain.
• You have a history of attention difficulties. The dopaminergic mechanism can produce modest cognitive sharpening as a side benefit.

Avoid bupropion if:

• You have a history of seizure disorder, eating disorders, or severe head injury.
• You are currently on MAO inhibitors or recently discontinued them.
• You have uncontrolled hypertension.
• You have active bipolar disorder without mood stabilization.
• You are pregnant. Bupropion’s pregnancy data is mixed; most clinicians prefer NRT during pregnancy. Our quit vaping during pregnancy guide covers the broader framework.

Consider an alternative if:

• You want the strongest single-agent efficacy. Varenicline has higher head-to-head quit rates.
• You want over-the-counter access. NRT (patches, gum, lozenges, pouches) is OTC and inexpensive. Our NRT guide covers the field.
• You are waiting for cytisinicline approval (PDUFA target June 20, 2026). Our cytisinicline availability timeline covers the expected launch window.

Combination Approaches

The strongest cessation evidence supports combination protocols over single-agent treatment in hard cases.

Bupropion + nicotine patch: Adds a small but meaningful efficacy bump over either alone. Useful for users with high relapse risk or who have failed single-agent attempts. Our combination NRT patch + lozenge guide covers the patch component.

Bupropion + behavioral counseling. Evidence-based combination. Behavioral support roughly doubles the efficacy of any pharmacological intervention.

Bupropion + breakthrough NRT (gum, lozenges, pouches). Common in clinical practice. The breakthrough NRT handles acute cravings while bupropion provides baseline dopamine support.

For users layering pouches into the protocol, our best nicotine pouches to quit vaping guide covers the dose-matching framework.

Cost and Access

Bupropion SR generic costs $10-30 per month at most U.S. pharmacies with insurance, $40-80 without insurance using discount cards. Branded Wellbutrin and Zyban run substantially higher — typically $150-300/month — and offer no meaningful clinical advantage over generic. Insurance coverage for bupropion (any indication) is essentially universal, including under Medicare Part D and Medicaid.

Bottom Line

Bupropion is a real option that gets under-prescribed for vaping cessation. The efficacy is lower than varenicline but better than placebo by a substantial margin, the side effect profile is gentler for most users, the cost is low, and it treats co-occurring depression as a same-pill bonus. For users who have failed varenicline or who want a nicotine-free pharmacological path, it is the right tool. Talk to your prescriber about timing — start 1-2 weeks before your quit date, plan for a 7-12 week course, and pre-plan how you’ll handle the post-treatment window when the drug clears the system.

How long does bupropion take to work for quitting?

Bupropion takes 7-14 days to reach therapeutic effect for cessation. You start the drug 1-2 weeks before your quit date and continue vaping at your usual pattern during the pre-quit window. The quit date typically falls at the start of week 2 of bupropion.

What’s the difference between Wellbutrin and Zyban?

None pharmacologically. Wellbutrin and Zyban are the same molecule (bupropion) at the same doses. Wellbutrin is labeled for depression; Zyban is labeled for smoking cessation. Generic bupropion SR is the same drug at substantially lower cost.

Can I take bupropion with nicotine patches?

Yes. Bupropion plus nicotine patch is a recognized combination protocol with small but meaningful efficacy gain over either alone. This is useful for users with high relapse risk or who have failed single-agent attempts.

What are the most common bupropion side effects?

Insomnia (most common, especially in the first 2 weeks), dry mouth, headache, mild nausea, and modest appetite suppression. Most early side effects resolve within 7-14 days. Taking the second dose no later than 5 PM helps minimize insomnia.

Is bupropion safer than Chantix for quitting vaping?

Different risk profiles. Bupropion has lower rates of nausea and abnormal dreams than varenicline (Chantix) but carries a small seizure risk that varenicline does not. For most users without contraindications, both drugs are reasonable choices; the right pick depends on your individual risk profile and history.